Nuvation Bio's market challenges, rising losses, and competitive pressures in oncology lead to an unfavorable risk/reward outlook. See why I rate NUVB a Sell.

Nuvation Bio is a Buy after FDA approval of Ibtrozi, a highly selective ROS1+ NSCLC treatment with strong clinical results and brain metastasis efficacy.

The completed Phase 1 portion enrolled ROS1-positive NSCLC patients who previously received at least one ROS1 TKI, or patients with other ROS1-positive solid tumors who had been previously treated.

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

NEW YORK, August 07, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second ...

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses ...

Stage-4 cancer patients are living longer, challenging the idea of what it means to have and survive cancer. “The science ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is conducting a ...

The event will bring together artists, filmmakers, sponsors, and supporters committed to celebrating Black culture and ...

The Evolving Heritage Gala is a celebration of Black Women in the UK, Africa, and Its Diaspora, honouring the remarkable ...